ReviewNature reviews. Endocrinology2017
Molecular profiling of thyroid nodule fine-needle aspiration cytology.
Review in Nature reviews. Endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Precision medicine in thyroid nodules: current strategies, challenges, and future directions.Hormones (Athens, Greece) · 2026Review
- Deciphering functional intra-tumoral heterogeneity in BRAFOncogene · 2026Article
- A targeted proteomics assay for the preoperative diagnosis of thyroid nodules.Cell reports. Medicine · 2026Article
- Utilities of next-generation sequencing in the surgical management of thyroid nodules in China.BMC endocrine disorders · 2026Article
- The FT4/FT3 ratio combined with thyroglobulin and parathyroid hormone for distinguishing benign from malignant thyroid nodules: a retrospective study based on histopathological diagnosis.Frontiers in medicine · 2026Article
- Diagnostic value of deep learning of multimodal imaging of thyroid for TI-RADS category 3-5 classification.Endocrine · 2025Article
- Article
- Is classic papillary thyroid carcinoma definitely an "indolent cancer"?-a case of locally advanced classic occult papillary thyroid carcinoma: a case report.AME case reports · 2025Article
- Blue light-driven cell cycle arrest in thyroid cancer via Retinal-OPN3 complex.Cell communication and signaling : CCS · 2024Article
- Application of microvascular ultrasound-assisted thyroid imaging report and data system in thyroid nodule risk stratification.Insights into imaging · 2024Article
- BRAF Detection in FNAC Combined with Semi-QuantitativeDiagnostics (Basel, Switzerland) · 2024Article
- GeneAI 3.0: powerful, novel, generalized hybrid and ensemble deep learning frameworks for miRNA species classification of stationary patterns from nucleotides.Scientific reports · 2024Article
- Thyroid Nodules: Emerging Trends in Detection and Visualization based on Citespace.Endocrine, metabolic & immune disorders drug targets · 2024Article
- From sequencing to validation: NGS-based exploration of plasma miRNA in papillary thyroid carcinoma.Frontiers in oncology · 2024Article
- Article
- Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cells.The Journal of clinical investigation · 2023Article
- Case Report: Giant abdominal hemangioma originating from the liver.Frontiers in oncology · 2023Article
- Do ACR TI-RADS scores demonstrate unique thyroid molecular profiles?Ultrasonography (Seoul, Korea) · 2022Article
- LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p.Cell death & disease · 2021Article
- Are the anatomical, clinical, and ultrasound characteristics of thyroid nodules with Bethesda III or IV cytology and ACR TI-RADS 3, 4, or 5 able to refine the indications for molecular diagnostic tests?Archives of endocrinology and metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The differential diagnosis and malignancy risk stratification of thyroid nodules requires multidisciplinary expertise and knowledge of both local ultrasonography practices and the local malignancy rates for a given fine-needle aspiration (FNA) result. Even in such a multidisciplinary setting, FNA cytology has the inherent limitation that indeterminate cytology results cannot distinguish between follicular adenomas, follicular thyroid carcinomas or follicular variant papillary thyroid carcinomas. Accumulating evidence suggests that this limitation can be overcome by using molecular diagnostic approaches. In this Review, we present the advantages and disadvantages of the different molecular diagnostic methodologies, which can be divided into two approaches: those that 'rule out' malignancy (to reduce the overtreatment of benign nodules) and those that 'rule in' malignancy (to optimize surgical planning). We identify microRNA classifiers as potential additional markers for use in a two-step diagnostic approach, consider the potential implications of the reclassification of noninvasive encapsulated follicular variant papillary thyroid carcinomas to noninvasive follicular thyroid neoplasms with papillary-like nuclear features and discuss the cost-effectiveness of molecular testing. Molecular FNA diagnostics is an important complementary addition to FNA cytology that could substantially reduce unnecessary surgery and better define the need for appropriate surgery in patients who have thyroid nodules with indeterminate FNA cytology.
Indexed as
Identifiers
28361927What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.